Technology
Health
Biotechnology

Akebia Therapeutics

$8.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.31 (-3.56%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AKBA and other stocks, options, ETFs, and crypto commission-free!

About

Akebia Therapeutics, Inc. Common Stock, also called Akebia Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for hypoxia-inducible factor. Read More It also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. It offers vadadustat, which is an oral therapy for the treatment of anemia due to chronic kidney disease. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Employees
114
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
478.62M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
750.34K
High Today
$8.96
Low Today
$8.38
Open Price
$8.65
Volume
550.43K
52 Week High
$11.60
52 Week Low
$5.20

Collections

Technology
Health
Biotechnology
Therapy
Biopharmaceutical
Pharmaceutical
2014 IPO
US

News

The Motley FoolMar 19

Akebia Therapeutics (AKBA) Q4 2018 Earnings Conference Call Transcript

Akebia Therapeutics (NASDAQ:AKBA) Q4 2018 Earnings Conference Call March 18, 2019 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Akebia Therapeutics preliminary full-year 2018 financial results and business highlights conference call. As a reminder, this conference call is being recorded. [Operator instructions] I would now like to introduce your host for today's conference. Megan, the flo...

187
BusinessWireMar 18

Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced preliminary financial results for the full year ended December 31, 2018 and business highlights. “2018 was a transformational year for Akebia,” said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. “We successfully executed a number of strategic initiatives to a...

208
The Motley FoolMar 12

Why Akebia Therapeutics, Momo, and Switch Jumped Today

The stock market generally kept gaining ground on Tuesday, with only downward pressure from the most heavily weighted component of the Dow Jones Industrial Average preventing a clean sweep of every major benchmark posting solid gains.

824

Earnings

-$0.64
-$0.34
-$0.05
$0.25
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.24 per share
Actual
Available Mar 18, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.